| Clinical data | |
|---|---|
| License data | |
| Pregnancy category |
|
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.217.751 |
| Chemical and physical data | |
| Formula | C24H33Cl2NO5 |
| Molar mass | 486.43 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Vilanterol is an ultra-long-acting β2-adrenoceptor agonist which was approved in May 2013 in combination with fluticasone furoate for sale as Breo Ellipta by GlaxoSmithKline for the treatment of chronic obstructive pulmonary disease (COPD). The combination is also approved for the treatment of asthma in Canada, Europe, Japan and New Zealand.
Vilanterol is available in following combinations:
{{cite web}}: CS1 maint: multiple names: authors list (link)